Propranolol vs Ivabradine for POTS
Trial Summary
What is the purpose of this trial?
1.0 BACKGROUND Postural tachycardia syndrome (POTS) is a disorder of chronic orthostatic intolerance characterized by symptoms of palpitations, lightheadedness, chest discomfort, shortness of breath, blurred vision, and mental clouding. These symptoms occur during standing and are associated with a marked increase in heart rate (HR) in the absence of hypotension, which typically resolve when sitting or lying down. Most importantly, POTS is associated with a very poor quality of life and significant functional disability. POTS patients commonly experience mental clouding ("brain fog") even while lying down or seated, which poses significant limitations to daily activities . Unfortunately, there is a relative paucity in the literature assessing therapies for POTS patients. Given that excessive tachycardia on standing is a fundamental component of this syndrome, a handful of studies have evaluated medications that reduce HR. Ivabradine is newer drug that is a selective If channel blocker that reduces HR without affecting other cardiovascular functions. 2.0 RATIONALE / STUDY PURPOSE The investigators propose to compare the efficacy of propranolol and ivabradine on HR response to standing, and symptom burden in patients with POTS. 3.0 Study Design This will be a single-center double-blind placebo-controlled randomized crossover trial conducted in patients with POTS to compare effects of (1) oral ivabradine 5 mg bid plus placebo BID (to fill out a QID schedule); (2) oral propranolol 10 mg qid; and (3) oral placebo qid in POTS patients. After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of either ivabradine, propranolol or placebo. The other two treatments will be given in separate 4-week courses with a 7-day washout period between phases, with each participant acting as his or her own control. At the end of each 4-week phase, participants will complete the symptom-rating and HRQOL questionnaires, and also undergo tilt table testing to assess the change in HR at 10 min with head up tilt. Participants will undergo POTS testing at baseline and at the end of each 4-week treatment course. This will involve a total of 4 separate study visits.
Will I have to stop taking my current medications?
Participants must stop taking certain medications before joining the trial. There is a 7-day washout period (time without taking certain medications) required before starting the study treatments. If you are currently on beta-blockers or ivabradine, you need to be able to safely stop them before the study.
What data supports the effectiveness of the drug propranolol for treating POTS?
Is propranolol generally safe for human use?
Propranolol has been studied in various formulations and is generally considered safe for human use, as it has been used effectively for conditions like angina, hypertension, and hyperthyroidism. Studies have shown that different brands and formulations of propranolol do not significantly differ in their safety profiles.23678
How does the drug propranolol differ from other treatments for POTS?
Propranolol is a beta-blocker that works by slowing down the heart rate, which can help manage symptoms of POTS (Postural Orthostatic Tachycardia Syndrome) by reducing the heart's workload. Unlike some other treatments, propranolol has been shown to have a consistent bioavailability across different brands, ensuring reliable effects in controlling heart rate.124910
Research Team
Satish R Raj, MD
Principal Investigator
University of Calgary
Eligibility Criteria
This trial is for adults aged 18-60 with Postural Tachycardia Syndrome (POTS) who can consent to participate. Excluded are those with low heart rates or blood pressure, structural heart disease, diabetes, uncontrolled asthma, pregnancy, severe liver issues, certain medication use and specific heart rhythm problems.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase 1
Participants receive a 4-week course of either ivabradine, propranolol, or placebo, followed by a 7-day washout period.
Treatment Phase 2
Participants receive a 4-week course of the second treatment (ivabradine, propranolol, or placebo), followed by a 7-day washout period.
Treatment Phase 3
Participants receive a 4-week course of the final treatment (ivabradine, propranolol, or placebo).
Follow-up
Participants are monitored for safety and effectiveness after treatment.
Treatment Details
Interventions
- Ivabradine
- Propranolol
Ivabradine is already approved in United States, European Union, Canada for the following indications:
- Heart failure
- Angina
- Angina
- Heart failure
- Angina
- Heart failure
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor
Dysautonomia International
Collaborator